Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Fortress Biotech, Inc. (NASDAQ: FBIO).

Full DD Report for FBIO

You must become a subscriber to view this report.


Recent News from (NASDAQ: FBIO)

Mustang Bio Announces Updates on CAR T Cell Therapy Clinical Trials with City of Hope
First-of-its-kind Phase 1 clinical trial using intraventricular delivery of CAR T cells to brains of patients with HER2-positive breast cancer with brain metastases now enrolling patients First patient dosed in Phase 1 clinical trial of HER2-specific memory-enriched T cells in treatin...
Source: GlobeNewswire
Date: October, 30 2018 08:00
Checkpoint Therapeutics to Present at Ladenburg Thalmann 2018 Healthcare Conference
NEW YORK, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a Fortress Biotech (NASDAQ: FBIO) company, today announced that James F. Oliviero, President and Chief Executive Officer of Checkpoint, will present a company overview at ...
Source: GlobeNewswire
Date: September, 27 2018 08:00
National Announces Expansion of Equity Research Team
NEW YORK, Sept. 27, 2018 (GLOBE NEWSWIRE) -- National Holdings Corporation (NASDAQ: NHLD) (“National” or the “Company”), a leading full-service independent brokerage, investment banking, trading, insurance, accounting and asset management firm, today announced th...
Source: GlobeNewswire
Date: September, 27 2018 07:30
Checkpoint Therapeutics Announces Encouraging Safety and Efficacy Data from Phase 1/2 Clinical Trial of EGFR Inhibitor CK-101
6 of 8 pts (75%) ORR in treatment-naïve EGFR mutation-positive NSCLC patients Well-tolerated with unremarkable safety profile; No DLTs or related SAEs Phase 3 trial in treatment-naïve EGFR mutation-positive NSCLC patients targeted to commence in 2019 NEW YORK, Sept. 0...
Source: GlobeNewswire
Date: September, 06 2018 07:30
Mustang Bio Announces Presentations on CAR T Therapies at 4th Annual CAR-TCR Summit 2018
NEW YORK, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a Fortress Biotech (NASDAQ: FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology and gene...
Source: GlobeNewswire
Date: September, 04 2018 07:15
Mustang Bio to Participate in September Investor Conferences
NEW YORK, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a Fortress Biotech (NASDAQ: FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology and gene ...
Source: GlobeNewswire
Date: August, 30 2018 08:00
Checkpoint Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
NEW YORK, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a Fortress Biotech (NASDAQ: FBIO) company, today announced that James F. Oliviero, President and Chief Executive Officer of Checkpoint, will present a company overview at t...
Source: GlobeNewswire
Date: August, 30 2018 08:00
Mustang Bio: Prudent Expansion Into Gene Therapy
There are many good reasons why an investor might decide to sell common stocks. He may want to build a new home or finance his son in a business. Any one of a number of similar reasons can, from the standpoint of happy living, make selling common stock sensible. - The Father of Growth Invest...
Source: SeekingAlpha
Date: August, 24 2018 12:27
National Holdings Corporation Announces Expansion of Capital Markets Team
NEW YORK, Aug. 20, 2018 (GLOBE NEWSWIRE) -- National Holdings Corporation (NASDAQ: NHLD) (“National” or the “Company”), a leading full-service independent brokerage, investment banking, trading insurance accounting and asset management firm, today announced the e...
Source: GlobeNewswire
Date: August, 20 2018 07:33
Checkpoint Therapeutics: Potential For A Near-Term Run Up
Shares of Checkpoint Therapeutics ( CKPT ) have fallen by around 60% since the firm´s common stock began trading on the NASDAQ in June of last year. In the past, I´ve been slightly biased against Fortress Biotech and its subsidiaries, whether due to pure skepticism, its controllin...
Source: SeekingAlpha
Date: August, 14 2018 10:58

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-071.1991.1351.20411.1397,542
2018-12-061.231.211.301.2189,889
2018-12-051.301.241.351.24119,550
2018-12-041.301.261.351.2487,375
2018-12-031.241.291.311.23101,886

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0723,64053,93943.8273Short
2018-12-0610,58921,27149.7814Short
2018-12-0418,11936,10650.1828Short
2018-12-0316,19747,57534.0452Cover
2018-11-304,10023,99517.0869Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on FBIO.


About Fortress Biotech, Inc. (NASDAQ: FBIO)

Logo for Fortress Biotech, Inc. (NASDAQ: FBIO)

We are a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of inflammatory diseases and cancer.

 

 

 

Current Management

  • Bobby W. Sandage / President, CEO
  • Noah D. Beerman / EVP, COO
  • Dale Ritter / VP, Fin., Chief Accounting Officer, Acting CFO
  • Glenn L. Cooper / Executive Chairman
  • Eric K. Rowinsky / Vice Chairman
  • David J. Barrett /
  • Jimmie Harvey, Jr. /
  • J. Jay Lobell /
  • Michael W. Rogers /
  • Lindsay A. Rosenwald /
  • Bobby W. Sandage /

Current Share Structure

  • Market Cap: $190,283,118 - 05/16/2018
  • Authorized: 100,000,000 - 05/01/2018
  • Issue and Outstanding: 52,275,582 - 05/01/2018

 


Recent Filings from (NASDAQ: FBIO)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 30 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: April, 20 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: April, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 16 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 16 2018
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: March, 13 2018

 

 


Daily Technical Chart for (NASDAQ: FBIO)

Daily Technical Chart for (NASDAQ: FBIO)


Stay tuned for daily updates and more on (NASDAQ: FBIO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: FBIO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in FBIO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of FBIO and does not buy, sell, or trade any shares of FBIO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/